TSX: MFI
www.mapleleaffoods.com
Meat Protein delivers top-line growth of 3.8% and
Adjusted EBITDA Margin of 9.0% in the quarter
Plant Protein targeting neutral or better Adjusted EBITDA in the
latter half of 2023
MISSISSAUGA, ON, Aug. 4, 2022
/PRNewswire/ - Maple Leaf Foods Inc. ("Maple Leaf Foods" or
the "Company") (TSX: MFI) today reported its financial results for
the second quarter ended June 30, 2022.
"This chaotic and unpredictable operating environment is
unprecedented in my 40-year career in the food industry," said
Michael H. McCain, President and CEO
of Maple Leaf Foods. "Driven by a post-pandemic economy and the
tragic conflict in Eastern Europe,
we have been unable to hire adequate people resources to operate
our supply chains, experienced unnatural agricultural and trading
markets, and realized hyper-inflation that has been challenging to
keep up with pricing. While our Q2 results fell short of
expectations with an Adjusted EBITDA margin of 9% in the Meat
Protein Group, we see signs of these conditions abating. Our
commitment to achieve 14-16% Adjusted EBITDA was grounded in the
assumption of normal, five-year average market conditions and we
are confident we will deliver that once the environment stabilizes,
although predicting this timeline at the moment is challenging. Our
focus on executing our Blueprint to be the most sustainable protein
company on earth is absolute."
"In our Plant Protein business, we are in full motion executing
our transition to a different business model," continued Mr.
McCain. "At the end of Q2, we took steps to materially reduce the
size of the organization. We expect to achieve our SG&A targets
by the end of this year, and a right sizing of the manufacturing
footprint in the first half of 2023, giving us the back half of
2023 as time to make final adjustments. Revenue management
adjustments will also occur over the course of the next 12 months.
This is a business model in transition back to one of profitable
growth."
Second Quarter 2022
Highlights
- Total Company sales grew 3.1% to $1,195.1 million, with an Adjusted Earnings
Before Interest, Taxes, Depreciation and Amortization
("EBITDA")(i) Margin of 6.2%.
- Meat Protein Group sales grew to $1,160.2 million, an increase of 3.8% year over
year. Adjusted EBITDA was $104.1
million, and Adjusted EBITDA Margin was 9.0%.
- In the Plant Protein Group, the Company recorded an
$18.6 million restructuring charge
and took steps to rightsize its Selling, General and Administrative
expenses ("SG&A") spend as part of the journey towards Adjusted
EBITDA neutrality in the second half of 2023.
- Capital expenditures were $89.7
million and consisted mainly of Construction
Capital(i) of $49.9
million, primarily related to the London, Ontario poultry facility.
Outlook
- Meat Protein: Expect mid-to-high single digit sales
growth in 2022, and Adjusted EBITDA Margin expansion to achieve a
target range of 14% - 16% when market conditions normalize.
- Plant Protein: Targeting to deliver neutral or better
Adjusted EBITDA in the latter half of 2023.
(i)
|
Refer to the section
titled Non-IFRS Financial Measures in this news
release.
|
Financial Highlights
|
As at or for
the
|
|
|
As at or for
the
|
Measure(i)
(Unaudited)
|
Three months ended
June 30,
|
|
Six months ended
June 30,
|
|
2022
|
|
2021
|
|
Change
|
|
2022
|
|
2021
|
|
Change
|
Sales
|
$
|
1,195.1
|
$
|
1,158.9
|
|
3.1 %
|
$
|
2,321.7
|
|
2,211.9
|
$
|
5.0 %
|
Net (Loss)
Earnings
|
$
|
(54.6)
|
$
|
8.8
|
|
(722.4) %
|
$
|
(40.9)
|
|
56.5
|
$
|
(172.5) %
|
Basic (Loss) Earnings
per Share
|
$
|
(0.44)
|
$
|
0.07
|
|
(728.6) %
|
$
|
(0.33)
|
|
0.46
|
$
|
(171.7) %
|
Adjusted Operating
Earnings(ii)(iii)
|
$
|
23.6
|
$
|
58.3
|
|
(59.5) %
|
$
|
39.7
|
|
109.8
|
$
|
(63.8) %
|
Adjusted Earnings per
Share(ii)(iii)
|
$
|
0.00
|
$
|
0.29
|
|
(100) %
|
$
|
0.03
|
|
0.56
|
$
|
(94.6) %
|
Adjusted EBITDA - Meat
Protein Group(ii)(iii)
|
$
|
104.1
|
$
|
131.2
|
|
(20.7) %
|
$
|
201.6
|
|
255.1
|
$
|
(21.0) %
|
Sales - Plant Protein
Group
|
$
|
40.8
|
$
|
48.1
|
|
(15.2) %
|
$
|
85.7
|
|
90.7
|
$
|
(5.5) %
|
Free Cash
Flow(ii)
|
$
|
(70.6)
|
$
|
(135.9)
|
|
48.1 %
|
$
|
(257.4)
|
|
(331.1)
|
$
|
22.3 %
|
Construction
Capital(ii)
|
|
|
|
|
|
|
$
|
665.8
|
|
720.8
|
$
|
(7.6) %
|
Net
Debt(ii)
|
|
|
|
|
|
|
$
|
(1,421.2)
|
|
(1,068.2)
|
$
|
33.0 %
|
(i)
|
All financial
measures in millions of dollars except Basic and Adjusted Earnings
per Share.
|
(ii)
|
Refer to the section
titled Non-IFRS Financial Measures in this news
release.
|
(iii)
|
Certain comparative
figures have been restated to conform with current year
presentation.
|
Sales for the second quarter of 2022 were $1,195.1 million compared to $1,158.9 million last year, an increase of 3.1%,
driven by higher sales in the Meat Protein Group, partially offset
by lower sales in the Plant Protein Group. For more details on
sales performance by operating segment, refer to the section
entitled Operating Review.
Year-to-date sales for 2022 were $2,321.7
million compared to $2,211.9
million last year, an increase of 5.0%, due to similar
factors as noted above.
Net loss for the second quarter of 2022 was $54.6 million ($0.44 per basic share) compared to earnings of
$8.8 million ($0.07 per basic share) last year. The net loss
resulted from weaker commercial performance due to cost inflation
and labour challenges, as well as higher restructuring costs and
start-up expenses.
Year-to-date net loss for 2022 was $40.9
million ($0.33 per basic
share) compared to earnings of $56.5
million ($0.46 per basic
share) last year. The net loss resulted from weaker commercial
performance due to cost inflation and labour challenges, as well as
higher restructuring costs and start-up expenses.
Adjusted Operating Earnings for the second quarter of 2022 were
$23.6 million compared to
$58.3 million last year, and Adjusted
Earnings per Share for the second quarter of 2022 were $0.00 compared to $0.29 last year due to similar factors as noted
above.
Year-to-date Adjusted Operating Earnings for 2022 were
$39.7 million compared to
$109.8 million last year, and
Adjusted Earnings per Share for 2022 were $0.03 compared to $0.56 last year due to similar factors as noted
above.
For further discussion on key metrics and a discussion of
results by operating segment, refer to the section titled Operating
Review.
Note: Several items are excluded from the discussions of
underlying earnings performance as they are not representative of
ongoing operational activities. Refer to the section entitled
Non-IFRS Financial Measures at the end of this news release for a
description and reconciliation of all non-IFRS financial
measures.
Response to COVID-19
As an essential service, Maple Leaf Foods is focused on
protecting the health and well-being of its people, maintaining
business continuity and broadening its social outreach. To manage
through this unprecedented environment, the Company has taken a
number of measures in its business and operating practices that
include heightened safety policies and procedures, adopting a
vaccination mandate for all employees and contractors, and close
communication and collaboration with public health authorities,
including hosting on-site vaccination clinics in 2021. The measures
enacted to protect the health and safety of employees have
increased the Company's current cost structure due to higher
labour, personal protective equipment, sanitation and other
expenses associated with the pandemic.
Overall, the Company believes its proactive and comprehensive
efforts have, and should continue to mitigate adverse operational
impacts. As the COVID-19 situation evolves, Maple Leaf Foods will
continue to adapt and adopt best practices that prioritize the
health and safety of its employees and the stability of the food
supply. As part of Maple Leaf Foods' broader social responsibility
since the pandemic began, the Company has provided extensive
support to front-line staff, emergency food relief efforts and
health care providers.
COVID-19 continues to have an impact on the global economy,
leading to increased inflation, labour shortages and disruptions in
the global supply chain. To date, the Company's leading brands,
revenue management capabilities and robust supply chain have
enabled it to mitigate these impacts. Maple Leaf Foods continues to
monitor the ongoing environment and believes it is well-positioned
to face these headwinds.
Operating Review
The Company has two reportable segments. These segments offer
different products, with separate organizational structures,
brands, financial, and marketing strategies. The Company's chief
operating decision makers regularly review internal reports for
these businesses: performance of the Meat Protein Group is based on
revenue growth, Adjusted Operating Earnings and Adjusted EBITDA,
while the performance of the Plant Protein Group in the short term
is focused on obtaining Adjusted EBITDA neutral or better
results.
The following table summarizes the Company's sales, gross
profit, SG&A, Adjusted Operating Earnings, Adjusted EBITDA, and
Adjusted EBITDA Margin by operating segment for the three months
ended June 30, 2022 and June 30, 2021.
|
Three months ended
June 30, 2022
|
Three months ended June
30, 2021
|
($
millions)(i) (Unaudited)
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Sales
|
$
1,160.2
|
40.8
|
(5.9)
|
$
1,195.1
|
$
1,117.5
|
48.1
|
(6.7)
|
$
1,158.9
|
Gross profit
(loss)
|
$
136.0
|
(10.1)
|
(38.7)
|
$
87.2
|
$ 167.0
|
0.3
|
(31.7)
|
$ 135.7
|
Selling, general and
administrative
expenses
|
$
87.3
|
26.3
|
—
|
$
113.6
|
$
81.2
|
29.8
|
—
|
$ 110.9
|
Adjusted Operating
Earnings(iii)(iv)
|
$
57.7
|
(34.0)
|
—
|
$
23.6
|
$
87.3
|
(29.1)
|
—
|
$
58.3
|
Adjusted
EBITDA(iii)(iv)
|
$
104.1
|
(30.0)
|
—
|
$
74.1
|
$ 131.2
|
(25.5)
|
—
|
$ 105.7
|
Adjusted EBITDA
Margin(iii)(iv)
|
9.0 %
|
(73.6) %
|
n/a
|
6.2 %
|
11.7 %
|
(53.1) %
|
n/a
|
9.1 %
|
(i)
|
Totals may not add
due to rounding.
|
(ii)
|
Non-allocated
includes eliminations of inter-segment sales and associated cost of
goods sold, changes in the fair value of biological
assets and derivatives, and non-allocated costs which are comprised
of expenses not separately identifiable to reportable segments
or are not part of the measures used by the Company when assessing
a segment's operating results.
|
(iii)
|
Refer to the section
titled Non-IFRS Financial Measures in this news
release.
|
(iv)
|
Certain comparatives
figures have been restated to conform with current year
presentation.
|
The following table summarizes the Company's sales, gross
profit, SG&A, Adjusted Operating Earnings, Adjusted EBITDA, and
Adjusted EBITDA Margin by operating segment for the six months
ended June 30, 2022 and June 30, 2021.
|
Six months ended
June 30, 2022
|
Six months ended June
30, 2021
|
($
millions)(i) (Unaudited)
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Sales
|
$
2,249.6
|
85.7
|
(13.6)
|
$
2,321.7
|
$
2,131.2
|
90.7
|
(9.9)
|
$
2,211.9
|
Gross profit
(loss)
|
$
266.9
|
(16.3)
|
(9.5)
|
$
241.1
|
$ 333.1
|
0.4
|
(4.9)
|
$ 328.6
|
Selling, general and
administrative
expenses
|
$
176.0
|
57.1
|
—
|
$
233.1
|
$ 168.3
|
58.6
|
—
|
$ 226.8
|
Adjusted Operating
Earnings(iii)(iv)
|
$
108.7
|
(68.9)
|
—
|
$
39.7
|
$ 167.0
|
(57.1)
|
—
|
$ 109.8
|
Adjusted
EBITDA(iii)(iv)
|
$
201.6
|
(60.7)
|
—
|
$
140.9
|
$ 255.1
|
(49.9)
|
—
|
$ 205.2
|
Adjusted EBITDA
Margin(iii)(iv)
|
9.0 %
|
(70.8) %
|
n/a
|
6.1 %
|
12.0 %
|
(55.0) %
|
n/a
|
9.3 %
|
(i)
|
Totals may not add
due to rounding.
|
(ii)
|
Non-allocated
includes eliminations of inter-segment sales and associated cost of
goods sold, changes in the fair value of biological
assets and derivatives, and non-allocated costs which are comprised
of expenses not separately identifiable to reportable segments
or
are not part of the measures used by the Company when assessing a
segment's operating results.
|
(iii)
|
Refer to the section
titled Non-IFRS Financial Measures in this news
release.
|
(iv)
|
Certain comparatives
figures have been restated to conform with current year
presentation.
|
Meat Protein Group
The Meat Protein Group is comprised of prepared meats,
ready-to-cook and ready-to-serve meals, value-added fresh pork and
poultry products that are sold to retail, foodservice and
industrial channels, and agricultural operations in pork and
poultry. The Meat Protein Group includes leading brands such as
Maple Leaf®, Maple Leaf Prime®, Maple Leaf Natural Selections®,
Schneiders®, Schneiders® Country Naturals®, Mina®, Greenfield
Natural Meat Co.®, and many leading regional brands.
Sales for the second quarter of 2022 increased 3.8% to
$1,160.2 million compared to
$1,117.5 million last year. Sales
growth was driven by pricing action to mitigate inflation and a
favourable mix-shift in product sales, including growth in
sustainable meats and branded products, partially offset by lower
sales volume.
Year-to-date sales for 2022 increased 5.6% to $2,249.6 million compared to $2,131.2 million last year. Sales growth was
driven by pricing actions to mitigate inflationary cost increases
and favourable mix-shift towards sustainable meats, branded
products and growth in sales to the
United States. These positive factors were partially offset
by lower sales volume.
Gross profit for the second quarter of 2022 was $136.0 million (gross margin of 11.7%) compared
to $167.0 million (gross margin of
14.9%) last year. Gross profit was negatively impacted by cost
inflation, labour shortages, and pork market headwinds, partially
offset by pricing action. Gross profit for the second quarter
included start-up expenses of $9.0
million (2021: $1.5 million)
associated with Construction Capital projects, which are excluded
in the calculation of Adjusted Operating Earnings.
Year-to-date gross profit for 2022 was $266.9 million (gross margin of 11.9%) compared
to $333.1 million (gross margin of
15.6%) last year. Gross profit was negatively impacted by
operational and supply chain disruptions, inflationary cost
increases, and pork market headwinds, partially offset by pricing
action. Gross profit year-to-date included start-up expenses of
$17.7 million (2021: $2.1 million) associated with Construction
Capital projects, which are excluded in the calculation of Adjusted
Operating Earnings.
SG&A expenses for the second quarter of 2022 were
$87.3 million compared to
$81.2 million last year. The increase
in SG&A expenses was largely driven by the timing of
advertising and promotional expenses and a gradual normalization of
discretionary spending.
Year-to-date SG&A expenses for 2022 were $176.0 million compared to $168.3 million last year. The increase in
SG&A expenses was driven by the timing of advertising and
promotional expenses, a gradual normalization of discretionary
spending and donations to support the relief efforts in
Ukraine.
Adjusted Operating Earnings for the second quarter of 2022 were
$57.7 million compared to
$87.3 million last year, consistent
with factors noted above.
Year-to-date Adjusted Operating Earnings for 2022 were
$108.7 million compared to
$167.0 million last year, consistent
with factors noted above.
Adjusted EBITDA for the second quarter of 2022 were $104.1 million compared to $131.2 million last year, driven by factors
consistent with those noted above. Adjusted EBITDA Margin for the
second quarter was 9.0% compared to 11.7% last year, also driven by
factors consistent with those noted above.
Year-to-date Adjusted EBITDA for 2022 were $201.6 million compared to $255.1 million last year, driven by factors
consistent with those noted above. Year-to-date Adjusted EBITDA
Margin for 2022 was 9.0% compared to 12.0% last year, also driven
by factors consistent with those noted above.
Plant Protein Group
The Plant Protein Group is comprised of refrigerated plant
protein products, premium grain-based protein, and vegan cheese
products sold to retail, foodservice and industrial channels. The
Plant Protein Group includes the leading brands Lightlife® and
Field Roast™.
Sales for the second quarter of 2022 decreased 15.1% to
$40.8 million compared to
$48.1 million last year. Excluding
the impact of foreign exchange, sales decreased 18.4%, driven by
lower volumes in retail products. This more than offset pricing
action implemented to mitigate inflation and structural cost
increases, and growth in foodservice volumes.
Year-to-date sales for 2022 decreased 5.5% to $85.7 million compared to $90.7 million last year. Excluding the impact of
foreign exchange, sales decreased 7.5%, driven by lower volumes in
retail products. This more than offset growth in foodservice
volumes and pricing action implemented to mitigate inflation and
structural cost increases.
Gross profit for the second quarter of 2022 was a loss of
$10.1 million (gross margin loss of
24.7%) compared to income of $0.3
million (gross margin of 0.6%) last year. The decrease in
gross profit was driven by inflationary costs and strategic
investments in capacity ahead of anticipated demand, which resulted
in increased overhead and short-term costs. This was partially
offset by pricing action. Gross profit for the quarter also
included start-up expenses of $2.3
million (2021: $0.4 million)
associated with Construction Capital projects which are excluded in
the calculation of Adjusted Operating Earnings.
Year-to-date gross profit for 2022 was a loss of $16.3 million (gross margin loss of 19.1%)
compared to income of $0.4 million
(gross margin of 0.5%) last year. The decrease in gross profit was
driven by inflationary costs and strategic investments in capacity
ahead of anticipated demand, which resulted in increased overhead
and short-term costs. This was partially offset by pricing action.
Year-to-date Gross profit also included start-up expenses of
$4.5 million (2021: $1.0 million) associated with Construction
Capital projects which are excluded in the calculation of Adjusted
Operating Earnings.
SG&A expenses for the second quarter of 2022 were
$26.3 million (64.4% of sales)
compared to $29.8 million (61.9% of
sales) last year. The decrease in SG&A expenses was primarily
attributable to lower advertising expenses, partially offset by
higher consulting and people costs.
Year-to-date SG&A expenses for 2022 were $57.1 million (66.6% of sales) compared to
$58.6 million (64.6% of sales) last
year. The decrease in SG&A expenses was primarily attributable
to lower advertising expenses, partially offset by higher
consulting and people costs.
Adjusted Operating Earnings for the second quarter of 2022 were
a loss of $34.0 million compared to a
loss of $29.1 million last year. The
decrease in Adjusted Operating Earnings is consistent with the
factors noted above.
Year-to-date Adjusted Operating Earnings for 2022 were a loss of
$68.9 million compared to a loss of
$57.1 million last year. The decrease
in Adjusted Operating Earnings is consistent with the factors noted
above.
Other Matters
On August 3, 2022, the Board of
Directors approved a quarterly dividend of $0.20 per share (an increase of $0.02 per share from the 2021 second quarter
dividends), $0.80 per share on an
annual basis, payable September 29,
2022 to shareholders of record at the close of business
September 8, 2022. Unless indicated
otherwise by the Company at or before the time the dividend is
paid, the dividend will be considered an eligible dividend for the
purposes of the "Enhanced Dividend Tax Credit System".
Conference Call
A conference call will be held at 8:00 a.m. ET on
August 4, 2022, to review Maple Leaf Foods' second quarter
financial results. To participate in the call, please dial
416-764-8650 or 1-888-664-6383. For those unable to participate,
playback will be made available an hour after the event at
416-764-8677 or 1-888-390-0541 (Passscode: 642262#).
A webcast of the second quarter conference call will also be
available at: https://www.mapleleaffoods.com
The Company's full unaudited consolidated interim financial
statements ("Consolidated Interim Financial Statements") and
related Management's Discussion and Analysis are available on the
Company's website.
An investor presentation related to the Company's second quarter
financial results is available at www.mapleleaffoods.com and can be
found under Presentations and Webcasts on the Investors page.
2022 Outlook
Maple Leaf Foods is a leading consumer protein company,
supported by a portfolio of market leading brands, a solid balance
sheet and capital structure that provide financial flexibility.
Over the last several years, the Company has developed a foundation
to pursue compelling growth vectors across its business and to
create value for all stakeholders.
Meat Protein Group
In Meat Protein, the Company's strategy is to drive profitable
growth. In 2017, Maple Leaf Foods articulated its target to reach
an Adjusted EBITDA Margin of 14% - 16% in 2022, assuming normal
market conditions, including a pork complex in-line with the 5-year
average.
Given the unprecedented market dynamics, marked by a challenging
post-pandemic economy, the conflict in Europe, high inflation and significant market
and supply chain disruption, Maple Leaf Foods expects that its Meat
Protein Group will achieve the following:
- Mid-to-high single digit sales growth in 2022, driven by
continued momentum in sustainable meats, leveraging brand
leadership, and growth into the U.S. market.
- Adjusted EBITDA Margin expansion to 14% - 16% target range once
markets normalize, driven by mix-shift benefits in prepared meats
resulting from growth in sustainable meats and brand renovation, as
well as operational efficiencies.
Plant Protein Group
- In late 2021, the Company announced that it was re-evaluating
its outlook for the Plant Protein Group and launching a
comprehensive review of the overall plant protein category. This
decision was driven by a pronounced slowdown in growth rates in the
category, particularly in the second half of the year, which fueled
the Company's imperative to identify and thoroughly assess the
causes, near and long-term trends, and overall implications. While
the Company's analysis is ongoing, the results to date confirm that
the very high category growth rates previously predicted by many
industry experts are unlikely to be achieved given current customer
feedback, experience, buy rates and household penetration. Based on
this new information, the Company believes that the category will
continue to grow at more modest, but still attractive rates.
Current estimates suggest that the category will grow at an average
annual rate of 10% to 15%, making it a $6
billion to $10 billion market
by 2030. Accordingly, the Company is pivoting its strategy and
investment thesis for the Plant Protein Group and has set a new
goal to deliver neutral or better Adjusted EBITDA in the latter
half of 2023. Work is ongoing to implement this pivot. Given the
current size of the Plant Protein Group of approximately
US$150 million of annual revenue in
2021, the expected resultant business model from this strategy
would deliver a 30% gross margin, with less than US$50 million in SG&A, to achieve the stated
Adjusted EBITDA target.
Capital
- The Company's capital expenditure estimate for the full year of
2022 remains unchanged and in the range of $400 million to $500
million, with approximately 50% to be comprised of
Construction Capital attributable to the construction of the
London, Ontario poultry facility
and the remainder largely relating to other projects to add growth
and capacity in the Prepared Meats business and to expand hog
production.
- The Company expects the London,
Ontario poultry facility to start to deliver approximately
$100 million annually of additional
Adjusted EBITDA once fully ramped up which is expected to be by the
end of 2023. Additionally, the Company expects the Bacon Centre of
Excellence to contribute approximately $30
million annually of additional Adjusted EBITDA once fully
ramped up which is expected to be in the second half of 2023.
The ongoing effects of COVID-19 induced supply chain disruptions
and the war in Ukraine are
unpredictable and may impact a number of factors that drive growth
in the business, including:
- Agricultural commodity and foreign exchange markets;
- Inflationary cost pressures;
- Disruptions in the global supply chain;
- Availability of labour; and
- The balance between retail and foodservice demand.
For more information on the impact of COVID-19 on the business
and the associated risks, refer to the section titled Response to
COVID-19, and for more information on the factors that may
influence future performance, see the section titled
Forward-Looking Statements in this news release.
The execution of the Company's financial and operational
priorities are embedded in a commitment to deliver shared value for
the benefit of all stakeholders. The Company's guiding pillars to
be the "Most Sustainable Protein Company on Earth" include Better
Food, Better Care, Better Communities, Better Planet and are core
to how Maple Leaf Foods conducts itself. To that end, the Company's
priorities include:
- Better Food - leading the real food movement and
transitioning key brands to 100% "raised without antibiotics".
- Better Care - further advancement of animal care, after
achieving our transition of all sows under management to open
housing systems in 2021.
- Better Communities - investing a minimum of
approximately 1% of pre-tax profit to advance sustainable food
security.
- Better Planet - continuing to amplify its commitment to
carbon neutrality, while focusing on eliminating waste in any
resources it consumes, including food, energy, water, packaging,
and time.
Non-IFRS Financial
Measures
The Company uses the following non-IFRS measures: Adjusted
Operating Earnings, Adjusted Earnings per Share, Adjusted EBITDA,
Adjusted EBITDA Margin, Construction Capital, Net Debt, Free Cash
Flow and Return on Net Assets. Management believes that these
non-IFRS measures provide useful information to investors in
measuring the financial performance of the Company for the reasons
outlined below. These measures do not have a standardized meaning
prescribed by IFRS and therefore they may not be comparable to
similarly titled measures presented by other publicly traded
companies and should not be construed as an alternative to other
financial measures determined in accordance with IFRS.
Adjusted Operating Earnings,
Adjusted EBITDA and Adjusted EBITDA Margin
Adjusted Operating Earnings, Adjusted EBITDA and Adjusted EBITDA
Margin are non-IFRS measures used by Management to evaluate
financial operating results. Adjusted Operating Earnings is defined
as earnings before other income, income taxes and interest expense
adjusted for items that are not considered representative of
ongoing operational activities of the business and items where the
economic impact of the transactions will be reflected in earnings
in future periods when the underlying asset is sold or transferred.
Adjusted EBITDA is defined as Adjusted Operating Earnings plus
depreciation and intangible asset amortization, adjusted for items
included in other expense that are considered representative of
ongoing operational activities of the business. Adjusted EBITDA
Margin is calculated as Adjusted EBITDA divided by sales.
The table below provides a reconciliation of earnings (loss)
before income taxes as reported under IFRS in the Consolidated
Interim Financial Statements to Adjusted Operating Earnings and
Adjusted EBITDA for the three and six months ended June 30,
2022 as indicated below. Management believes that these non-IFRS
measures are useful in assessing the performance of the Company's
ongoing operations and its ability to generate cash flows to fund
its cash requirements, including the Company's capital investment
program.
|
Three months ended
June 30, 2022
|
Three months ended June
30, 2021
|
($
millions)(i) (Unaudited)
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Earnings (loss)
before income taxes
|
$
46.4
|
(55.1)
|
(50.0)
|
$
(58.6)
|
$ 86.7
|
(29.6)
|
(42.9)
|
$
14.2
|
Interest expense and
other financing costs
|
—
|
—
|
10.8
|
10.8
|
—
|
—
|
5.7
|
5.7
|
Other expense
(income)
|
1.9
|
0.1
|
0.5
|
2.5
|
(2.0)
|
0.1
|
5.5
|
3.6
|
Restructuring and other
related costs
|
0.4
|
18.7
|
—
|
19.0
|
1.2
|
—
|
—
|
1.2
|
Earnings (loss) from
operations
|
$
48.6
|
(36.4)
|
(38.7)
|
$
(26.4)
|
$ 85.9
|
(29.5)
|
(31.7)
|
$
24.7
|
Start-up expenses from
Construction Capital(iii)(iv)
|
9.0
|
2.3
|
—
|
11.3
|
1.5
|
0.4
|
—
|
1.9
|
Change in fair value of
biological assets
|
—
|
—
|
50.0
|
50.0
|
—
|
—
|
51.9
|
51.9
|
Unrealized gain on
derivative contracts
|
—
|
—
|
(11.3)
|
(11.3)
|
—
|
—
|
(20.2)
|
(20.2)
|
Adjusted Operating
Earnings(iv)
|
$
57.7
|
(34.0)
|
—
|
$
23.6
|
$ 87.3
|
(29.1)
|
—
|
$
58.3
|
Depreciation and
amortization(iv)
|
48.3
|
4.1
|
—
|
52.4
|
45.8
|
3.7
|
—
|
49.4
|
Items included in other
income (expense)
representative of ongoing
operations(v)
|
(1.9)
|
(0.1)
|
—
|
(1.9)
|
(1.9)
|
(0.1)
|
—
|
(2.0)
|
Adjusted
EBITDA(iv)
|
$
104.1
|
(30.0)
|
—
|
$
74.1
|
$
131.2
|
(25.5)
|
—
|
$
105.7
|
Adjusted EBITDA
Margin(iv)
|
9.0 %
|
(73.6) %
|
n/a
|
6.2 %
|
11.7 %
|
(53.1) %
|
n/a
|
9.1 %
|
(i)
|
Totals may not add
due to rounding.
|
(ii)
|
Non-allocated
includes eliminations of inter-segment sales and associated cost of
goods sold, and non-allocated costs which are
comprised of income and expenses not separately identifiable to
reportable segments or are not part of the measures used by the
Company when assessing a segment's operating
results.
|
(iii)
|
Start-up expenses
are temporary costs as a result of operating new facilities that
are or have been classified as Construction Capital.
These costs can include training, product testing, yield and labour
efficiency variances, duplicative overheads and other temporary
expenses required to ramp-up production.
|
(iv)
|
Certain comparative
figures have been restated to conform with current year
presentation.
|
(v)
|
2022 primarily
includes certain costs associated with sustainability projects,
gains and losses on the sale of long-term assets, legal
settlements, and other miscellaneous expenses. 2021 primarily
includes certain costs associated with sustainability projects,
gains
and losses on the sale of long-term assets, and other miscellaneous
expenses..
|
|
Six months ended
June 30, 2022
|
Six months ended June
30, 2021
|
($
millions)(i)
(Unaudited)
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Earnings (loss)
before income taxes
|
$
84.2
|
(92.2)
|
(29.6)
|
$
(37.6)
|
$
162.9
|
(58.3)
|
(24.5)
|
$ 80.1
|
Interest expense and
other financing costs
|
—
|
—
|
18.5
|
18.5
|
—
|
—
|
10.7
|
10.7
|
Other expense
(income)
|
3.4
|
0.1
|
1.6
|
5.1
|
(0.9)
|
0.2
|
8.9
|
8.2
|
Restructuring and other
related costs
|
3.4
|
18.7
|
—
|
22.1
|
2.9
|
—
|
—
|
2.9
|
Earnings (loss) from
operations
|
$
91.0
|
(73.5)
|
(9.5)
|
$
8.0
|
$
164.9
|
(58.1)
|
(4.9)
|
$
101.8
|
Start-up expenses from
Construction Capital(iii)(iv)
|
17.7
|
4.5
|
—
|
22.2
|
2.1
|
1.0
|
—
|
3.1
|
Change in fair value of
biological assets
|
—
|
—
|
10.7
|
10.7
|
—
|
—
|
13.4
|
13.4
|
Unrealized loss (gain)
on derivative contracts
|
—
|
—
|
(1.2)
|
(1.2)
|
—
|
—
|
(8.5)
|
(8.5)
|
Adjusted Operating
Earnings(iv)
|
$
108.7
|
(68.9)
|
—
|
$
39.7
|
$
167.0
|
(57.1)
|
—
|
$
109.8
|
Depreciation and
amortization(iv)
|
96.3
|
8.3
|
—
|
104.6
|
91.2
|
7.4
|
—
|
98.7
|
Items included in other
income (expense)
representative of ongoing
operations(v)
|
(3.4)
|
(0.1)
|
—
|
(3.5)
|
(3.1)
|
(0.2)
|
—
|
(3.3)
|
Adjusted
EBITDA(iv)
|
$
201.6
|
(60.7)
|
—
|
$
140.9
|
$
255.1
|
(49.9)
|
—
|
$
205.2
|
Adjusted EBITDA
Margin(iv)
|
9.0 %
|
(70.8 %)
|
n/a
|
6.1 %
|
12.0 %
|
(55.0 %)
|
n/a
|
9.3 %
|
(i)
|
Totals may not add
due to rounding.
|
(ii)
|
Non-allocated
includes eliminations of inter-segment sales and associated cost of
goods sold, and non-allocated costs which are
comprised of income and expenses not separately identifiable to
reportable segments or are not part of the measures used by the
Company when assessing a segment's operating
results.
|
(iii)
|
Start-up expenses
are temporary costs as a result of operating new facilities that
are or have been classified as Construction Capital.
These costs can include training, product testing, yield and labour
efficiency variances, duplicative overheads and other temporary
expenses required to ramp-up production.
|
(iv)
|
Certain comparative
figures have been restated to conform with current year
presentation.
|
(v)
|
2022 primarily
includes certain costs associated with sustainability projects,
gains and losses on the sale of long-term assets, legal
settlements, and other miscellaneous expenses. 2021 primarily
includes certain costs associated with sustainability projects,
gains
and losses on the sale of long-term assets, and other miscellaneous
expenses.
|
Adjusted Earnings per
Share
Adjusted Earnings per Share, a non-IFRS measure, is used by
Management to evaluate financial operating results. It is defined
as basic earnings per share and is adjusted on the same basis as
Adjusted Operating Earnings. The table below provides a
reconciliation of basic earnings per share as reported under IFRS
in the Consolidated Interim Financial Statements to Adjusted
Earnings per Share for the three and six months ended June 30, as indicated below. Management believes
this basis is the most appropriate on which to evaluate financial
results as they are representative of the ongoing operations of the
Company.
($ per
share)
(Unaudited)
|
Three months ended
June 30,
|
Six months ended
June 30,
|
2022
|
2021
|
2022
|
2021
|
Basic (loss) earnings
per share
|
|
$
(0.44)
|
|
$
0.07
|
|
$
(0.33)
|
|
$
0.46
|
Restructuring and other
related costs(i)
|
|
0.13
|
|
0.01
|
|
0.15
|
|
0.02
|
Items included in other
expense not considered
representative of ongoing
operations(ii)
|
|
—
|
|
0.02
|
|
0.01
|
|
0.04
|
Start-up expenses from
Construction Capital(iii)(iv)
|
|
0.07
|
|
0.01
|
|
0.14
|
|
0.02
|
Change in fair value of
biological assets
|
|
0.30
|
|
0.31
|
|
0.06
|
|
0.08
|
Change in unrealized
fair value on derivatives
|
|
(0.07)
|
|
(0.12)
|
|
(0.01)
|
|
(0.05)
|
Adjusted Earnings
per Share(iv)(v)
|
|
$
0.00
|
|
$
0.29
|
|
$
0.03
|
|
$
0.56
|
(i)
|
Includes per share
impact of restructuring and other related costs, net of
tax.
|
(ii)
|
Primarily includes
legal fees and provisions and transaction related costs, net of
tax.
|
(iii)
|
Start-up expenses
are temporary costs as a result of operating new facilities that
are or have been classified as Construction Capital.
These costs can include training, product testing, yield and labour
efficiency variances, duplicative overheads and other temporary
expenses required to ramp-up production.
|
(iv)
|
Certain comparatives
figures have been restated to conform with current year
presentation.
|
(v)
|
Totals may not add
due to rounding.
|
Construction Capital
Construction Capital, a non-IFRS measure, is used by Management
to evaluate the amount of capital resources invested in specific
strategic development projects that are not yet operational. It is
defined as investments and related financing charges in projects
over $50.0 million that are related
to longer-term strategic initiatives, with no returns expected for
at least 12 months from commencement of construction and the asset
will be re-categorized from Construction Capital once operational.
The current balance of construction capital includes investments in
the London, Ontario poultry
production facility. The expansion of the Bacon Centre of
Excellence in Winnipeg, Manitoba,
was completed in the fourth quarter of 2021 and recategorized.
Investments in capacity at the Walker Drive facility in
Brampton, Ontario, and the plant
protein production facilities in Indiana were completed in the first quarter of
2022 and have been recategorized. The following table is a summary
of Construction Capital activity and debt financing for the periods
indicated below.
($
thousands) (Unaudited)
|
|
2022
|
|
2021
|
Property and
equipment and intangibles at January 1
|
$
|
2,554,483
|
$
|
2,062,683
|
Other capital and
intangible assets at January 1(i)
|
|
1,811,164
|
|
1,622,094
|
Construction Capital
at January 1
|
$
|
743,319
|
$
|
440,589
|
Additions(ii)
|
|
54,776
|
|
152,342
|
Transfers from
Construction Capital
|
|
(182,210)
|
|
—
|
Construction
Capital at March 31
|
$
|
615,885
|
$
|
592,931
|
Additions(ii)
|
|
49,903
|
|
127,822
|
Construction
Capital at June 30(iii)
|
$
|
665,788
|
$
|
720,753
|
Other capital and
intangible assets at June 30(i)
|
|
2,007,489
|
|
1,786,319
|
Property and
equipment and Intangibles at June 30
|
$
|
2,623,374
|
$
|
2,379,250
|
|
|
|
|
|
Construction Capital
debt financing(iv)
|
$
|
637,795
|
$
|
703,502
|
(i)
|
Other capital and
intangible assets consists of property and equipment and
intangibles that do not meet the definition of Construction
Capital.
|
(ii)
|
Certain comparative
figures have been restated to conform with current year
presentation.
|
(iii)
|
As at June 30, 2022,
the net book value of construction capital includes $2.1 million
related to intangible assets (June 30, 2021: $1.4
million; December 31, 2021: $2.5 million).
|
(iv)
|
Assumed to be fully
funded by debt to the extent that the Company has Net Debt
outstanding. Construction Capital debt financing
excludes interest paid and capitalized.
|
Net Debt
The following table reconciles Net Debt to amounts reported
under IFRS in the Company's Consolidated Interim Financial
Statements as at June 30, as
indicated below. The Company calculates Net Debt as cash and cash
equivalents, less long-term debt and bank indebtedness. Management
believes this measure is useful in assessing the amount of
financial leverage employed.
($
thousands)
(Unaudited)
|
|
As at June
30,
|
|
2022
|
|
2021
|
Cash and cash
equivalents
|
$
|
92,971
|
$
|
58,878
|
Current portion of
long-term debt
|
$
|
(1,029)
|
$
|
(5,235)
|
Long-term
debt
|
|
(1,513,124)
|
|
(1,121,865)
|
Total
debt
|
$
|
(1,514,153)
|
$
|
(1,127,100)
|
Net
Debt
|
$
|
(1,421,182)
|
$
|
(1,068,222)
|
Free Cash Flow
Free Cash Flow, a non-IFRS measure, is used by Management to
evaluate cash flow after investing in the maintenance or expansion
of the Company's asset base. It is defined as cash provided by
operations, less cash additions to long-term assets and capitalized
interest. The following table calculates Free Cash Flow for the
periods indicated below:
($
thousands)
(Unaudited)
|
Three months ended
June 30,
|
Six months ended
June 30,
|
|
2022
|
|
2021
|
|
2022
|
|
2021
|
Cash provided by (used
in) operating
activities
|
|
$
16,492
|
|
$
29,971
|
|
$
(68,501)
|
|
$
(263)
|
Additions to long-term
assets
|
|
(81,935)
|
|
(161,273)
|
|
(179,240)
|
|
(322,240)
|
Interest paid and
capitalized
|
|
(5,123)
|
|
(4,638)
|
|
(9,620)
|
|
(8,609)
|
Free Cash
Flow
|
|
$
(70,566)
|
|
$
(135,940)
|
|
$
(257,361)
|
|
$
(331,112)
|
Return on Net Assets
Return on Net Assets ("RONA") is calculated by dividing tax
effected earnings from operations (adjusted for items which are not
considered representative of the underlying operations of the
business) by average monthly net assets. Net assets are defined as
total assets (excluding cash and deferred tax assets) less
non-interest bearing liabilities (excluding deferred tax
liabilities). Management believes that RONA is an appropriate basis
upon which to evaluate long-term financial performance.
Forward-Looking
Statements
This document contains, and the Company's oral and written
public communications often contain, "forward-looking information"
within the meaning of applicable securities law. These statements
are based on current expectations, estimates, projections, beliefs,
judgments and assumptions based on information available at the
time the applicable forward-looking statement was made and in light
of the Company's experience combined with its perception of
historical trends. Such statements include, but are not limited to,
statements with respect to objectives and goals, in addition to
statements with respect to beliefs, plans, targets, goals,
objectives, expectations, anticipations, estimates, and intentions.
Forward-looking statements are typically identified by words such
as "anticipate", "continue", "estimate", "expect", "may", "will",
"project", "should", "could", "would", "believe", "plan", "intend",
"design", "target", "undertake", "view", "indicate", "maintain",
"explore", "entail", "schedule", "objective", "strategy", "likely",
"potential", "outlook", "aim", "propose", "goal", and similar
expressions suggesting future events or future performance. These
statements are not guarantees of future performance and involve
assumptions, risks and uncertainties that are difficult to
predict.
By their nature, forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results or events to differ materially from those
anticipated in such forward-looking statements. The Company
believes the expectations reflected in the forward-looking
statements are reasonable, but no assurance can be given that these
expectations will prove to be correct and such forward-looking
statements should not be unduly relied upon.
Specific forward-looking information in this document may
include, but is not limited to, statements with respect to:
- implications of COVID-19, including implications for supply
chain, workforce availability and consumption patterns;
- future performance, including future financial objectives,
goals and targets, category growth analysis, expected capital spend
and expected SG&A expenditures for the Company and each of its
operating segments;
- the execution of the Company's business strategy, including the
development and expected timing of business initiatives, brand
expansion and repositioning, plant protein category investment and
performance, and other growth opportunities, as well as the impact
thereof;
- the impact of international trade conditions and markets on the
Company's business, including access to markets, implications
associated with the spread of foreign animal disease (such as
African Swine Fever ("ASF")) and other animal diseases such as
Avian Influenza, as well as other social, economic and political
factors that affect trade, including the war in Ukraine;
- competitive conditions and the Company's ability to position
itself competitively in the markets in which it competes;
- capital projects, including planning, construction, estimated
expenditures, schedules, approvals, expected capacity, in-service
dates and anticipated benefits of construction of new facilities
and expansions of existing facilities;
- the Company's dividend policy, including future levels and
sustainability of cash dividends, the tax treatment thereof and
future dividend payment dates;
- the impact of commodity prices on the Company's operations and
financial performance, including the use and effectiveness of
hedging instruments;
- expected future cash flows and the sufficiency thereof, sources
of capital at attractive rates, future contractual obligations,
future financing options, renewal of credit facilities, and
availability of capital to fund growth plans, operating obligations
and dividends;
- operating risks, including the execution, monitoring and
continuous improvement of the Company's food safety programs,
animal health initiatives and cost reduction initiatives;
- the implementation, cost and impact of environmental
sustainability initiatives, as well as the anticipated future cost
of remediating environmental liabilities;
- the adoption of new accounting standards and the impact of such
adoption on the financial position of the Company;
- expectations regarding pension plan performance, including
future pension plan assets, liabilities and contributions; and
- developments and implications of actual or potential legal
actions.
Various factors or assumptions are typically applied by the
Company in drawing conclusions or making the forecasts,
projections, predictions or estimations set out in the
forward-looking statements. These factors and assumptions are based
on information currently available to the Company, including
information obtained by the Company from third-party sources and
include but are not limited to the following:
- expectations regarding the impact and future implications of
COVID-19 and adaptations in operations, supply chain, customer and
consumer behaviour, economic patterns and international trade;
- the competitive environment, associated market conditions and
market share metrics, category growth or contraction, the expected
behaviour of competitors and customers and trends in consumer
preferences;
- the success of the Company's business strategy, including
execution of the strategy in the Meat Protein Group and the outcome
of the category analysis related to the strategy for the Plant
Protein Groups;
- prevailing commodity prices, interest rates, tax rates and
exchange rates;
- the impact of the war in Ukraine on international relations, trade and
markets, as well as the economic condition of and the
sociopolitical dynamics between Canada, the U.S., Japan and China, and the ability of the Company to
access markets and source ingredients and other inputs in light of
global sociopolitical disruption;
- the spread of foreign animal disease (including ASF and Avian
Influenza), preparedness strategies to manage such spread, and
implications for all protein markets;
- the availability of capital to fund future capital requirements
associated with existing operations, assets and projects;
- expectations regarding participation in and funding of the
Company's pension plans;
- the availability of insurance coverage to manage certain
liability exposures;
- the extent of future liabilities and recoveries related to
legal claims;
- prevailing regulatory, tax and environmental laws; and
- future operating costs and performance, including the Company's
ability to achieve operating efficiencies and maintain high sales
volumes, high turnover of inventories and high turnover of accounts
receivable.
Readers are cautioned that these assumptions may prove to be
incorrect in whole or in part. The Company's actual results may
differ materially from those anticipated in any forward-looking
statements.
Factors that could cause actual results or outcomes to differ
materially from the results expressed, implied, or projected in the
forward-looking statements contained in this document include,
among other things, risks associated with the following:
- implications of COVID-19 on the operations and financial
performance of the Company, as well the implications for macro
socio-economic trends;
- competition, market conditions and the activities of
competitors and customers, including the expansion or contraction
of key categories (including plant protein);
- the health status of livestock, including the impact of
potential pandemics;
- international trade and access to markets and supplies, as well
as social, political and economic dynamics, including the war in
Ukraine;
- availability of and access to capital;
- decision respecting the return of capital to shareholders;
- the execution of capital projects, including cost, schedule and
regulatory variables;
- food safety, consumer liability and product recalls;
- cyber security and the maintenance and operation of the
Company's information systems and processes;
- climate change;
- strategic risk management, including the outcome of the
analysis of the plant protein category;
- acquisitions and divestitures;
- fluctuations in the debt and equity markets;
- fluctuations in interest rates and currency exchange
rates;
- pension assets and liabilities;
- cyclical nature of the cost and supply of hogs and the
competitive nature of the pork market generally;
- the effectiveness of commodity and interest rate hedging
strategies;
- impact of changes in the market value of the biological assets
and hedging instruments;
- the supply management system for poultry in Canada;
- availability of plant protein ingredients;
- intellectual property, including product innovation, product
development, brand strategy and trademark protection;
- consolidation of operations and focus on protein;
- the use of contract manufacturers;
- reputation;
- weather;
- compliance with government regulation and adapting to changes
in laws;
- actual and threatened legal claims;
- consumer trends and changes in consumer tastes and buying
patterns;
- environmental regulation and potential environmental
liabilities;
- consolidation in the retail environment;
- employment matters, including complying with employment laws
across multiple jurisdictions, the potential for work stoppages due
to non-renewal of collective agreements, recruiting and retaining
qualified personnel, reliance on key personnel and succession
planning;
- pricing of products;
- managing the Company's supply chain;
- changes in International Financial Reporting Standards and
other accounting standards that the Company is required to adhere
to for regulatory purposes; and
- other factors as set out under the heading "Risk Factors" in
the Company's Management Discussion and Analysis for the year ended
December 31, 2021.
The Company cautions readers that the foregoing list of factors
is not exhaustive.
Readers are further cautioned that some of the forward-looking
information, such as statements concerning future capital
expenditures, Adjusted EBITDA Margin growth in the Meat Protein
Group, and Adjusted EBITDA target in the Plant Protein Group
(including the timing, pace and impact of restructuring
activities), may be considered to be financial outlooks for
purposes of applicable securities legislation. These financial
outlooks are presented to evaluate potential future earnings and
anticipated future uses of cash flows and may not be appropriate
for other purposes. Readers should not assume these financial
outlooks will be achieved.
More information about risk factors can be found under the
heading "Risk Factors" in the Company's Annual Management's
Discussion and Analysis for the year ended December 31, 2021, that is available on SEDAR at
www.sedar.com. The reader should review such section in detail.
Additional information concerning the Company, including the
Company's Annual Information Form, is available on SEDAR at
www.sedar.com.
All forward-looking statements included herein speak only as of
the date hereof. Unless required by law, the Company does not
undertake any obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise. All forward-looking statements
contained herein are expressly qualified by this cautionary
statement.
About Maple Leaf Foods
Inc.
Maple Leaf Foods is a carbon neutral company with a vision to be
the most sustainable protein company on earth, responsibly
producing food products under leading brands including Maple Leaf®,
Maple Leaf Prime®, Maple Leaf Natural Selections®, Schneiders®,
Schneiders® Country Naturals®, Mina®, Greenfield Natural Meat Co.®,
Lightlife® and Field Roast™. The Company employs approximately
13,500 people and does business primarily in Canada, the U.S. and Asia. The Company is headquartered in
Mississauga, Ontario and its
shares trade on the Toronto Stock Exchange (MFI).
Consolidated Interim Balance
Sheets
(In thousands of
Canadian dollars)
(Unaudited)
|
As at June
30,
2022
|
|
As at June 30,
2021(i)
|
As at December
31,
2021
|
ASSETS
|
|
|
|
|
(Audited)
|
Cash and cash
equivalents
|
$
|
92,971
|
$
|
58,878
|
$
|
162,031
|
Accounts
receivable
|
|
191,199
|
|
201,027
|
|
167,082
|
Notes
receivable
|
|
62,609
|
|
66,297
|
|
33,294
|
Inventories
|
|
507,489
|
|
442,152
|
|
409,677
|
Biological
assets
|
|
129,181
|
|
118,445
|
|
138,209
|
Income taxes
recoverable
|
|
6,297
|
|
1,830
|
|
1,830
|
Prepaid expenses and
other assets
|
|
50,774
|
|
52,810
|
|
24,988
|
Assets held for
sale
|
|
604
|
|
—
|
|
—
|
Total current
assets
|
$
|
1,041,124
|
$
|
941,439
|
$
|
937,111
|
Property and
equipment
|
|
2,262,609
|
|
2,008,904
|
|
2,189,165
|
Right-of-use
assets
|
|
158,328
|
|
180,579
|
|
161,662
|
Investments
|
|
22,667
|
|
15,370
|
|
22,326
|
Employee
benefits
|
|
15,873
|
|
—
|
|
—
|
Other long-term
assets
|
|
22,747
|
|
8,851
|
|
11,644
|
Deferred tax
asset
|
|
48,725
|
|
24,775
|
|
39,907
|
Goodwill
|
|
662,261
|
|
655,415
|
|
658,673
|
Intangible
assets
|
|
360,765
|
|
370,346
|
|
365,318
|
Total long-term
assets
|
$
|
3,553,975
|
$
|
3,264,240
|
$
|
3,448,695
|
Total
assets
|
$
|
4,595,099
|
$
|
4,205,679
|
$
|
4,385,806
|
LIABILITIES AND
EQUITY
|
|
|
|
|
|
|
Accounts payable and
accruals
|
$
|
545,432
|
$
|
500,876
|
$
|
526,189
|
Current portion of
provisions
|
|
32,680
|
|
886
|
|
842
|
Current portion of
long-term debt
|
|
1,029
|
|
5,235
|
|
5,176
|
Current portion of
lease obligations
|
|
37,522
|
|
40,276
|
|
31,375
|
Income taxes
payable
|
|
—
|
|
14,396
|
|
23,853
|
Other current
liabilities
|
|
43,106
|
|
59,862
|
|
81,265
|
Total current
liabilities
|
$
|
659,769
|
$
|
621,531
|
$
|
668,700
|
Long-term
debt
|
|
1,513,124
|
|
1,121,865
|
|
1,247,073
|
Lease
obligations
|
|
142,462
|
|
154,457
|
|
144,391
|
Employee
benefits
|
|
64,964
|
|
90,879
|
|
97,629
|
Provisions
|
|
16,197
|
|
44,555
|
|
44,650
|
Other long-term
liabilities
|
|
2,232
|
|
6,022
|
|
1,057
|
Deferred tax
liability
|
|
176,680
|
|
140,957
|
|
146,380
|
Total long-term
liabilities
|
$
|
1,915,659
|
$
|
1,558,735
|
$
|
1,681,180
|
Total
liabilities
|
$
|
2,575,428
|
$
|
2,180,266
|
$
|
2,349,880
|
Shareholders'
equity
|
|
|
|
|
|
|
Share
capital
|
$
|
862,688
|
$
|
840,230
|
$
|
847,016
|
Retained
earnings
|
|
1,160,951
|
|
1,210,225
|
|
1,212,244
|
Contributed
surplus
|
|
9,969
|
|
3,186
|
|
5,371
|
Accumulated other
comprehensive income (loss)
|
|
11,979
|
|
(9,490)
|
|
(2,459)
|
Treasury
stock
|
|
(25,916)
|
|
(18,738)
|
|
(26,246)
|
Total shareholders'
equity
|
$
|
2,019,671
|
$
|
2,025,413
|
$
|
2,035,926
|
Total liabilities
and equity
|
$
|
4,595,099
|
$
|
4,205,679
|
$
|
4,385,806
|
(i)
|
Restated, see Note
16(a) of the Company's 2022 second quarter consolidated financial
statements.
|
Consolidated Interim Statements of
Net (Loss) Earnings
(In thousands of
Canadian dollars, except share
amounts)
(Unaudited)
|
Three months ended
June 30,
|
Six months ended
June 30,
|
|
2022
|
|
2021
|
|
2022
|
|
2021
|
|
|
|
|
|
|
|
|
|
Sales
|
$
|
1,195,133
|
$
|
1,158,861
|
$
|
2,321,686
|
$
|
2,211,944
|
Cost of goods
sold
|
|
1,107,894
|
|
1,023,205
|
|
2,080,584
|
|
1,883,334
|
Gross profit
|
$
|
87,239
|
$
|
135,656
|
$
|
241,102
|
$
|
328,610
|
Selling, general and
administrative expenses
|
|
113,608
|
|
110,924
|
|
233,065
|
|
226,804
|
(Loss) earnings before
the following:
|
$
|
(26,369)
|
$
|
24,732
|
$
|
8,037
|
$
|
101,806
|
Restructuring and other
related costs
|
|
19,039
|
|
1,190
|
|
22,057
|
|
2,858
|
Other
expense
|
|
2,452
|
|
3,617
|
|
5,076
|
|
8,159
|
(Loss) earnings before
interest and income taxes
|
$
|
(47,860)
|
$
|
19,925
|
$
|
(19,096)
|
$
|
90,789
|
Interest expense and
other financing costs
|
|
10,786
|
|
5,711
|
|
18,502
|
|
10,679
|
(Loss) earnings before
income taxes
|
$
|
(58,646)
|
$
|
14,214
|
$
|
(37,598)
|
$
|
80,110
|
Income tax (recovery)
expense
|
|
(4,034)
|
|
5,440
|
|
3,327
|
|
23,644
|
Net (loss)
earnings
|
$
|
(54,612)
|
$
|
8,774
|
$
|
(40,925)
|
$
|
56,466
|
|
|
|
|
|
|
|
|
|
(Loss) earnings per
share attributable to common
shareholders:
|
|
|
|
|
|
|
|
|
Basic (loss) earnings
per share
|
$
|
(0.44)
|
$
|
0.07
|
$
|
(0.33)
|
$
|
0.46
|
Diluted (loss)
earnings per share
|
$
|
(0.44)
|
$
|
0.07
|
$
|
(0.33)
|
$
|
0.45
|
Weighted average number
of shares (millions):
|
|
|
|
|
|
|
|
|
Basic
|
|
124.1
|
|
123.4
|
|
124.0
|
|
123.3
|
Diluted
|
|
124.1
|
|
125.5
|
|
124.0
|
|
125.5
|
Consolidated Interim Statements of
Other Comprehensive
Income (Loss)
(In thousands of
Canadian dollars)
(Unaudited)
|
Three months ended
June 30,
|
Six months ended
June 30,
|
|
2022
|
|
2021
|
|
2022
|
|
2021
|
|
|
|
|
|
|
|
|
|
Net (loss)
earnings
|
$
|
(54,612)
|
$
|
8,774
|
$
|
(40,925)
|
$
|
56,466
|
Other comprehensive
income
|
|
|
|
|
|
|
|
|
Actuarial gains
(losses) that will not be reclassified
to profit or loss (Net of tax of $0.2 million and
$13.6 million; 2021: $0.1 million and $24.9 million)
|
$
|
505
|
$
|
233
|
$
|
39,406
|
$
|
73,161
|
Items that are or may
be reclassified subsequently to
profit or loss:
|
|
|
|
|
|
|
|
|
Change in accumulated
foreign currency translation
adjustment (Net of tax of $0.0 million and $0.0
million; 2021: $0.0 million and $0.0 million)
|
|
15,063
|
|
(4,685)
|
|
8,092
|
|
(10,150)
|
Change in foreign
exchange on long-term debt
designated as a net investment hedge (Net of tax
of $1.7 million and $1.1 million; 2021: $0.8 million
and $1.5 million)
|
|
(9,085)
|
|
3,464
|
|
(5,525)
|
|
7,282
|
Change in cash flow
hedges (Net of tax of $0.7
million and $4.1 million; 2021: $0.5 million and
$2.4 million)
|
|
1,907
|
|
1,201
|
|
11,871
|
|
6,792
|
Total items that are or
may be reclassified
subsequently to profit or loss
|
$
|
7,885
|
$
|
(20)
|
$
|
14,438
|
$
|
3,924
|
Total other
comprehensive income
|
$
|
8,390
|
$
|
213
|
$
|
53,844
|
$
|
77,085
|
Comprehensive (loss)
income
|
$
|
(46,222)
|
$
|
8,987
|
$
|
12,919
|
$
|
133,551
|
Consolidated Interim Statements of
Changes in Total Equity
|
|
|
|
|
Accumulated
other comprehensive
income (loss)(i)
|
|
|
|
(In thousands of Canadian dollars)
(Unaudited)
|
|
Share
capital
|
Retained
earnings
|
Contributed
surplus
|
Foreign
currency
translation
adjustment
|
Unrealized
gains and
losses on
cash flow
hedges
|
Unrealized
gains on fair
value of
investments
|
Treasury
stock
|
|
Total
equity
|
Balance at December
31, 2021
|
$
|
847,016
|
1,212,244
|
5,371
|
2,037
|
(7,441)
|
2,945
|
(26,246)
|
$
|
2,035,926
|
Net loss
|
|
—
|
(40,925)
|
—
|
—
|
—
|
—
|
—
|
|
(40,925)
|
Other
comprehensive income (loss)(ii)
|
|
—
|
39,406
|
—
|
2,567
|
11,871
|
—
|
—
|
|
53,844
|
Dividends declared
($0.40 per
share)
|
|
—
|
(49,774)
|
—
|
—
|
—
|
—
|
—
|
|
(49,774)
|
Share-based
compensation
expense
|
|
—
|
—
|
13,758
|
—
|
—
|
—
|
—
|
|
13,758
|
Modification of stock
compensation
plan
|
|
—
|
—
|
(3,594)
|
—
|
—
|
—
|
—
|
|
(3,594)
|
Deferred taxes on
share-based
compensation
|
|
—
|
—
|
(800)
|
—
|
—
|
—
|
—
|
|
(800)
|
Exercise of stock
options
|
|
5,888
|
—
|
(1,289)
|
—
|
—
|
—
|
—
|
|
4,599
|
Shares purchased by
RSU trust
|
|
—
|
—
|
—
|
—
|
—
|
—
|
(7,500)
|
|
(7,500)
|
Settlement of
share-based
compensation
|
|
—
|
—
|
(15,560)
|
—
|
—
|
—
|
7,830
|
|
(7,730)
|
Change in obligation
for
repurchase of shares
|
|
9,784
|
—
|
12,083
|
—
|
—
|
—
|
—
|
|
21,867
|
Balance at June 30,
2022
|
$
|
862,688
|
1,160,951
|
9,969
|
4,604
|
4,430
|
2,945
|
(25,916)
|
$
|
2,019,671
|
|
|
|
|
|
Accumulated other
comprehensive
income (loss)(i)
|
|
|
|
(In thousands of Canadian dollars)
(Unaudited)
|
|
Share
capital
|
Retained
earnings
|
Contributed
surplus
|
Foreign
currency
translation
adjustment
|
Unrealized
gains and
losses on
cash flow
hedges
|
Unrealized
gains on fair
value of
investments
|
Treasury
stock
|
|
Total
equity
|
Balance at December 31,
2020
|
$
|
838,969
|
1,124,973
|
5,866
|
3,002
|
(16,416)
|
—
|
(23,930)
|
$
|
1,932,464
|
Net
earnings
|
|
—
|
56,466
|
—
|
—
|
—
|
—
|
—
|
|
56,466
|
Other
comprehensive income (loss)(ii)
|
|
—
|
73,161
|
—
|
(2,868)
|
6,792
|
—
|
—
|
|
77,085
|
Dividends declared
($0.36 per share)
|
|
—
|
(44,375)
|
—
|
—
|
—
|
—
|
—
|
|
(44,375)
|
Share-based
compensation
expense
|
|
—
|
—
|
9,229
|
—
|
—
|
—
|
—
|
|
9,229
|
Deferred taxes on
share-based
compensation
|
|
—
|
—
|
(450)
|
—
|
—
|
—
|
—
|
|
(450)
|
Exercise of stock
options
|
|
1,929
|
—
|
—
|
—
|
—
|
—
|
—
|
|
1,929
|
Settlement of
share-based
compensation
|
|
—
|
—
|
(9,679)
|
—
|
—
|
—
|
5,192
|
|
(4,487)
|
Change in obligation
for
repurchase of shares
|
|
(668)
|
—
|
(1,780)
|
—
|
—
|
—
|
—
|
|
(2,448)
|
Balance at June 30,
2021
|
$
|
840,230
|
1,210,225
|
3,186
|
134
|
(9,624)
|
—
|
(18,738)
|
$
|
2,025,413
|
(i)
|
Items that are or
may be subsequently reclassified to profit or
loss.
|
(ii)
|
Included in other
comprehensive income (loss) is the change in actuarial gains and
losses that will not be reclassified to profit or loss and has
been
reclassified to retained earnings.
|
Consolidated Interim Statements of
Cash Flows
(In thousands of
Canadian dollars)
(Unaudited)
|
Three months ended
June 30,
|
Six months ended
June 30,
|
2022
|
2021
|
2022
|
2021
|
CASH PROVIDED BY (USED
IN):
|
|
|
|
|
Operating
activities
|
|
|
|
|
|
|
|
|
Net (loss)
earnings
|
$
|
(54,612)
|
$
|
8,774
|
$
|
(40,925)
|
$
|
56,466
|
Add (deduct) items not
affecting cash:
|
|
|
|
|
|
|
|
|
Change in fair value
of biological assets
|
|
49,963
|
|
51,884
|
|
10,652
|
|
13,409
|
Depreciation and
amortization
|
|
57,239
|
|
50,199
|
|
114,430
|
|
100,401
|
Share-based
compensation
|
|
9,362
|
|
4,527
|
|
13,758
|
|
9,229
|
Deferred income
taxes
|
|
(3,160)
|
|
(16,054)
|
|
4,812
|
|
(9,870)
|
Income tax
current
|
|
(874)
|
|
21,494
|
|
(1,485)
|
|
33,514
|
Interest expense and
other financing costs
|
|
10,786
|
|
5,711
|
|
18,502
|
|
10,679
|
Loss on sale of
long-term assets
|
|
1,124
|
|
406
|
|
1,582
|
|
693
|
Impairment of property
and equipment and
ROU
assets
|
|
16,056
|
|
436
|
|
16,056
|
|
436
|
Change in fair value
of non-designated
derivatives
|
|
(14,109)
|
|
(18,044)
|
|
(12,535)
|
|
(8,417)
|
Change in net pension
obligation
|
|
1,944
|
|
(3,409)
|
|
4,442
|
|
(26)
|
Net income taxes
paid
|
|
(2,875)
|
|
(15,426)
|
|
(26,487)
|
|
(46,703)
|
Interest paid, net of
capitalized interest
|
|
(22,712)
|
|
(5,965)
|
|
(30,388)
|
|
(11,393)
|
Change in provision
for restructuring and other
related costs
|
|
1,743
|
|
(109)
|
|
3,456
|
|
(68)
|
Change in derivatives
margin
|
|
24,784
|
|
35,266
|
|
(319)
|
|
(396)
|
Other
|
|
(6,559)
|
|
(4,964)
|
|
(7,810)
|
|
(1,358)
|
Change in non-cash
operating working capital
|
|
(51,608)
|
|
(84,755)
|
|
(136,242)
|
|
(146,859)
|
Cash provided by (used
in) operating activities
|
$
|
16,492
|
$
|
29,971
|
$
|
(68,501)
|
$
|
(263)
|
Investing
activities
|
|
|
|
|
|
|
|
|
Additions to long-term
assets
|
$
|
(81,935)
|
$
|
(161,273)
|
$
|
(179,240)
|
$
|
(322,240)
|
Interest paid and
capitalized
|
|
(5,123)
|
|
(4,638)
|
|
(9,620)
|
|
(8,609)
|
Acquisition of
business
|
|
—
|
|
(40,151)
|
|
—
|
|
(40,151)
|
Proceeds from sale of
long-term assets
|
|
23
|
|
215
|
|
117
|
|
768
|
Cash used in investing
activities
|
$
|
(87,035)
|
$
|
(205,847)
|
$
|
(188,743)
|
$
|
(370,232)
|
Financing
activities
|
|
|
|
|
|
|
|
|
Dividends
paid
|
$
|
(24,901)
|
$
|
(22,267)
|
$
|
(49,774)
|
$
|
(44,375)
|
Net increase in
long-term debt
|
|
141,085
|
|
164,861
|
|
255,947
|
|
389,722
|
Payment of lease
obligation
|
|
(8,682)
|
|
(9,290)
|
|
(18,090)
|
|
(18,681)
|
Receipt of lease
inducement
|
|
—
|
|
—
|
|
6,847
|
|
—
|
Exercise of stock
options
|
|
881
|
|
523
|
|
4,599
|
|
1,929
|
Payment of financing
fees
|
|
(3,845)
|
|
(50)
|
|
(3,845)
|
|
(50)
|
Purchase of treasury
stock
|
|
(7,500)
|
|
—
|
|
(7,500)
|
|
—
|
Cash provided by
financing activities
|
$
|
97,038
|
$
|
133,777
|
$
|
188,184
|
$
|
328,545
|
Increase (decrease)
in cash and cash equivalents
|
$
|
26,495
|
$
|
(42,099)
|
$
|
(69,060)
|
$
|
(41,950)
|
Cash and cash
equivalents, beginning of period
|
|
66,476
|
|
100,977
|
|
162,031
|
|
100,828
|
Cash and cash
equivalents, end of period
|
$
|
92,971
|
$
|
58,878
|
$
|
92,971
|
$
|
58,878
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/maple-leaf-foods-reports-second-quarter-2022-financial-results-301599558.html
SOURCE Maple Leaf Foods Inc.